Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
| Revenue: $1M |
| Revenue Growth (YOY): inf% |
| Profit (% of Rev): 100.00% |
| Income (% of Rev): -1141.73% |
| Income Growth (YOY): -8.42% |
| Operating Income: $-13M |
| Operating Cash Flow: $-11M |
| Operating Cash Flow Growth (YoY): -17.76% |
| Annual Dividend Yield: 0.00% |
| Total Assets: $62M |
| Total Liabilities: $21M |
| Cash & Equivalent: $39M |
| Total Debt: $7M |
| Debt/Equity: 0.17 |
| Quick Ratio: 2.58 |
| Current Ratio: 2.58 |
| Price/Book: 6.79 |
| Price/Earnings: -5.32 |
| EBITDA: $-13M |
| EPS: -0.0466 |
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Buy.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.